Share price · GMAB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GMAB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Oct 2026+28.3%
- 23 Oct 2026+9.5%
- 5 Oct 2026+10.7%
- 15 Sep 2026+4.6%
- 30 Jun 2026+5.6%
- 2 Jun 2026-6.3%
Nothing announced by GMAB that day or the session before.
- 20 May 2026+6.0%
Nothing announced by GMAB that day or the session before.
- 3 Mar 2026-6.7%
- 4 Feb 2026-3.4%
- Day beforeGenmab: 6-K filing
- 23 Jan 2026+2.4%
Nothing announced by GMAB that day or the session before.
Share of unusual movement by asset
For each asset, the share of GMAB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(8 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | EGFR x c-METMultispecific antibody | Non-Small Cell Lung CancerColorectal CancerHead and Neck Squamous Cell Carcinoma | |
| Approved | CD20 x CD3Multispecific antibody | Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma | |
Tisotumab Vedotin Humax-tf-adc(Tivdak) | Approved | Tissue Factor (TF)Antibody–drug conjugate | Non-Small Cell Lung CancerCervical Cancer |
Zenocutuzumab(Bizengri) | Approved | HER2; HER3 (blocks NRG1 binding to HER3)Multispecific antibody | Non-Small Cell Lung CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma Cholangiocarcinoma |
| Phase 3 | Folate receptor alpha (FRα)Antibody–drug conjugate | Non-Small Cell Lung CancerBreast CancerOvarian CancerEndometrial Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 2 | EGFR x c-METMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1/2 | CD40 x 4-1BB (dual)Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | CD3 x FLT3Biologic (subtype unspecified) | Acute Myeloid Leukemia |
Upcoming events
(35 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (14)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
April 2027 (2)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (1)
What to watch
September 2027 (3)
What to watch
What to watch
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (2)
What to watch
What to watch
2028 (9)
March 2028 (2)
April 2028 (2)
September 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (2)
What to watch
What to watch
2029 (7)
January 2029 (1)
What to watch
February 2029 (1)
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (1)
What to watch
2030 (1)
March 2030 (1)
What to watch
2032 (2)
2037 (1)
November 2037 (1)
What to watch
Regulatory and conference events
(11)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | — | — | $1.8B | — | report ↗ |
For the third quarter of 2025, Genmab did not disclose revenue, R&D spend, or net income/loss in the provided material. The company reported cash and equivalents of $1,761M, with no quarterly net burn figure provided.
Genmab announced it will discontinue clinical development of acasunlimab following a portfolio review, prioritizing late-stage programs including EPKINLY (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S). The company stated that this decision does not impact its full year 2025 financial guidance.
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q2 | $780M | $361M | $622M | — | report ↗ |
| 2023-Q2 | $614M | $271M | $1.6B | — | report ↗ |
| 2022-Q2 | $453M | $183M | $1.4B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.7B | — | — | — | report ↗ |
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 270 reporting institutions held 81.9M shares ($2.2B, 13.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Orbis Allan Gray Ltd | 12,925,578 | $346.8M |
| 2 | ALLIANCEBERNSTEIN L.P. | 9,557,149 | $294.4M |
| 3 | Paradigm Biocapital Advisors LP | 7,967,836 | $213.8M |
| 4 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 4,975,324 | $133.5M |
| 5 | BlackRock, Inc. | 4,536,565 | $121.7M |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 4,414,550 | $118.4M |
| 7 | Deep Track Capital, LP | 3,663,250 | $98.3M |
| 8 | Harding Loevner LP | 3,231,601 | $86.7M |
| 9 | DEERFIELD MANAGEMENT COMPANY, L.P. | 2,462,000 | $66.1M |
| 10 | FIRST TRUST ADVISORS LP | 2,461,342 | $66.0M |
| 11 | TWO SIGMA INVESTMENTS, LP | 2,339,432 | $62.8M |
| 12 | MORGAN STANLEY | 2,184,701 | $58.6M |
| 13 | FEDERATED HERMES, INC. | 1,251,590 | $33.6M |
| 14 | FRANKLIN RESOURCES INC | 1,193,145 | $32.0M |
| 15 | Pictet Asset Management Holding SA | 1,077,471 | $28.9M |